United States - English - NLM (National Library of Medicine)

usantibiotics, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin es-600 is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors:      - antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) daycare attendance [s ee microbiology (12.4) ]. limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both s. pneumoniae (penicillin mic less than or equal to 2 mcg/ml) and the

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 500mg+ 125mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

smithkline beecham limited - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets film-coated - 875mg+ 125mg

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin sodium 1060.2mg equivalent to amoxicillin 1000 mg;  ; potassium clavulanate 238.25mg equivalent to clavulanic acid 200 mg;  ;  ;   - powder for injection - 1.2 g - active: amoxicillin sodium 1060.2mg equivalent to amoxicillin 1000 mg   potassium clavulanate 238.25mg equivalent to clavulanic acid 200 mg       - augmentin is indicated for the short term treatment of common bacterial infections such as: -upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media -lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia -genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections -skin and soft tissue infections -bone and joint infections: e.g. osteomyelitis -other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections augmentin is indicated for prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg;  ; potassium clavulanate 119.13mg equivalent to clavulanic acid 100 mg;  ;  ;   - powder for injection - 600 mg - active: amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg   potassium clavulanate 119.13mg equivalent to clavulanic acid 100 mg       - augmentin is indicated for the short term treatment of common bacterial infections such as: -upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media -lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia -genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections -skin and soft tissue infections -bone and joint infections: e.g. osteomyelitis -other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections augmentin is indicated for prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery.

United States - English - NLM (National Library of Medicine)

allegis pharmaceuticals, llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - augmentin is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: - lower respiratory tract infections - caused by beta‑lactamase–producing isolates of haemophilus influenzae and moraxella catarrhalis . - acute bacterial otitis media - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - sinusitis - caused by beta‑lactamase–producing isolates of h. influenzae and m. catarrhalis . - skin and skin structure infections - caused by beta‑lactamase–producing isolates of staphylococcus aureus , escherichia coli , and klebsiella species. - urinary tract infections - caused by beta‑lactamase–producing isolates of e. coli , klebsiella species, and enterobacter species. limitations of use when susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, augmentin should not b

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - potassium clavulanate, quantity: 7.4 mg/ml (equivalent: clavulanic acid, qty 6.25 mg/ml); amoxicillin trihydrate, quantity: 28.7 mg/ml (equivalent: amoxicillin, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: silicon dioxide; hypromellose; aspartame; succinic acid; xanthan gum; colloidal anhydrous silica; flavour - augmentin is indicated in the treatment of the following infections when caused by augmentin sensitive, beta-lactamase producing organisms: skin and skin structure infections, including cases caused by beta-lactamase producing s. aureus, e. coli and klebsiella spp. (only some strains may be sensitive). urinary tract infections, including cases caused by beta-lactamase producing e. coli, p. mirabilis & klebsiella spp. upper respiratory tract infections, such as sinusitis, including cases caused by beta-lactamase producing h.influenzae and m.catarrhalis, and otitis media, especially cases caused by beta-lactamase producing h. influenzae, m. catarrhalis and s. aureus. lower respiratory tract infections, especially cases caused by beta-lactamase producing h.influenzae and m.catarrhalis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin. however, when there is reason to believe an infection may involve any

United States - English - NLM (National Library of Medicine)

dr reddys laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - augmentin es-600 powder for oral suspension is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology, microbiology.] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 powder for oral suspension is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg/ml. therapy may be instituted prior to obtaining the

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - amoxicillin trihydrate; potassium clavulanate - oral tablet - 500mg ; 125mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - powder for suspension - clavulanic acid as potassium salt 11.4 mg/ml; amoxicillin as trihydrate 80 mg/ml - amoxicillin and enzyme inhibitor - augmentin is indicated for the treatment of the following infections in adults and children: • acute bacterial sinusitis (adequately diagnosed)• acute otitis media• acute exacerbations of chronic bronchitis (adequately diagnosed)• community acquired pneumonia• cystitis• pyelonephritis• skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.• bone and joint infections, in particular osteomyelitis.• recurrent tonsillitis